Skip to content
Application 206528
- Type
- ANDA
- Sponsor
- AJANTA PHARMA LTD
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | MEMANTINE HYDROCHLORIDE | MEMANTINE HYDROCHLORIDE | TABLET;ORAL | 5MG | No | No |
| 002 | MEMANTINE HYDROCHLORIDE | MEMANTINE HYDROCHLORIDE | TABLET;ORAL | 10MG | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 27241-070 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma Limited | ANDA | Current |
| 27241-070 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma USA Inc. | ANDA | Current |
| 27241-070 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma Limited | ANDA | Current |
| 27241-070 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma USA Inc. | ANDA | Current |
| 27241-071 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma Limited | ANDA | Current |
| 27241-071 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma USA Inc. | ANDA | Current |
| 27241-071 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma Limited | ANDA | Current |
| 27241-071 | Memantine Hydrochloride | Memantine Hydrochloride | Ajanta Pharma USA Inc. | ANDA | Current |
| 63629-7333 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |
| 71335-0346 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |
| 71335-0346 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |
| 71335-0346 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |
| 71335-1899 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |
| 71335-1899 | Memantine Hydrochloride | Memantine Hydrochloride | Bryant Ranch Prepack | ANDA | Current |